---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-007055"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:13:04.536567+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aclaris reports Q1 net loss $16.9M, down 40% YoY; advances ATI-2138 into Phase 2a for AD

## Summary
- Net loss narrowed to $16.9M from $28.2M YoY; total revenue $2.4M, flat.
- Cash and marketable securities $161.4M at March 31, 2024; expects lower quarterly cash burn ahead.
- Progressing ATI-2138 (ITK/JAK3 inhibitor) into Phase 2a proof-of-concept trial for moderate-to-severe atopic dermatitis.
- Seeking global development partner for lepzacitinib (topical JAK 1/3 inhibitor) after positive Phase 2b AD data.
- R&D expenses fell to $9.8M from $22.6M, driven by wind-down of programs and workforce reduction.

## SEC filing metadata
- accession: 0001558370-24-007055
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837024007055/0001558370-24-007055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837024007055/acrs-20240507x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-007055
- JSON: https://secwatch.observer/filing/0001558370-24-007055.json
- Plain text: https://secwatch.observer/filing/0001558370-24-007055.txt

## Key facts
- Earnings Releases
  Aclaris Therapeutics, Inc. reported first quarter of 2024 results: revenue $2.4 million, net income Net loss was $16.9 million.
  - Period: first quarter of 2024
  - Revenue: $2.4 million
  - Net income: Net loss was $16.9 million
  - Result: reported results
  source text: ​ Financial Results First Quarter 2024 ● Net loss was $16.9 million for the first quarter of 2024 compared to $28.2 million for the first quarter of 2023. ● Total revenue was $2.4 million for the first quarter of 2024 compared to $2.5 million for the first quarter of 2023. The decrease was primarily driven by lower contract research revenue during the three months
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000155837024007055/0001558370-24-007055-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.